From YMB about Zalicus and Novartis clinical trials :
Just a few that have recently been updated and are fairly new since the collaboration started. Looks like the Novartis partnership is alive and well. Too many to list here. The list goes on and on......
Just look at clinical trials(dot)gov and you will find a boat load of combination drug trials for cancer and there genotypes. This certainly lines up to what Mr. Corrigan referred to at the ASCO-NCI-EORTC Molecular Markers meeting.
Not yet open to enrollment-6/2012- A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER
Currently recruiting-4/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
10/2010- A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
5/2012- A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
9/2011-An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor?) in Combination With BEZ235 in Patients With Advanced Solid Tumors
6/2010-A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.
5/2012-A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer
Source: http://finance.yahoo.com/mbview/threadview/;_...d%2C1
(0)
(0)
